GlassScriptPhysician profile
Adrian Bersabe
NPI 1336432756
$4,658.98
in general payments reported to CMS, 2019-2025
49 companies · $1,334 in 2025
The $1,334 reported for 2025 was more than what a typical Hematology & Oncology provider received nationally (typical 2025 total: $686).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2019: $575 · 2020: $426 · 2021: $448 · 2022: $306 · 2023: $883 · 2024: $687 · 2025: $1,334.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $2,772 · Education: $132.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $2,771.64 |
| Education | $132.21 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Merck Sharp & Dohme LLC | $534.95 | 2019-2025 | Keytruda, Lynparza, Reblozyl |
| Regeneron Healthcare Solutions, INC. | $399.21 | 2021-2025 | Libtayo |
| Sanofi-Aventis U.S. LLC | $346.93 | 2020-2023 | |
| Genzyme Corporation | $331.90 | 2019-2025 | |
| Ipsen Biopharmaceuticals, INC | $259.46 | 2019-2024 | Onivyde |
| Daiichi Sankyo INC. | $253.00 | 2020-2025 | Enhertu, Datroway, Vanflyta |
| Incyte Corporation | $193.46 | 2021-2025 | Monjuvi, Jakafi, Zynyz |
| E.R. Squibb & Sons, L.L.C. | $181.44 | 2020-2025 | Opdivo, Abecma |
| Beigene USA, INC. | $162.26 | 2020-2023 | Brukinsa |
| Stemline Therapeutics INC. | $156.52 | 2023-2024 | Orserdu |
| Abbvie INC. | $156.12 | 2019-2023 | Venclexta |
| Emd Serono, INC. | $153.95 | 2022-2023 | Bavencio |
| Celgene Corporation | $127.00 | 2024-2025 | Reblozyl |
| Astrazeneca Pharmaceuticals LP | $115.39 | 2020-2025 | Calquence, Enhertu, Tezspire |
| Genentech USA, INC. | $107.57 | 2019-2025 | Polivy |
Show all 49 companies
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Adrian Bersabe listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.